[go: up one dir, main page]

WO2006034510A3 - Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease - Google Patents

Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease Download PDF

Info

Publication number
WO2006034510A3
WO2006034510A3 PCT/US2005/034763 US2005034763W WO2006034510A3 WO 2006034510 A3 WO2006034510 A3 WO 2006034510A3 US 2005034763 W US2005034763 W US 2005034763W WO 2006034510 A3 WO2006034510 A3 WO 2006034510A3
Authority
WO
WIPO (PCT)
Prior art keywords
cicletanine
combination
disease
agents
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/034763
Other languages
French (fr)
Other versions
WO2006034510A2 (en
Inventor
Glenn Cornett
Jim Page
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/035,308 external-priority patent/US20060153934A1/en
Priority claimed from US11/035,328 external-priority patent/US20060154959A1/en
Priority claimed from US11/035,231 external-priority patent/US20060154971A1/en
Priority claimed from US11/232,724 external-priority patent/US20060089374A1/en
Application filed by Individual filed Critical Individual
Priority to EP05800096A priority Critical patent/EP1804795A4/en
Priority to CA002581337A priority patent/CA2581337A1/en
Publication of WO2006034510A2 publication Critical patent/WO2006034510A2/en
Publication of WO2006034510A3 publication Critical patent/WO2006034510A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Preferred embodiments of the present invention are related to novel therapeutic drugs and drug combinations, and associated methods, for treating and/or preventing complications in patients with diabetes, metabolic syndrome, and/or hypertension. More particularly, aspects of the present invention are related to the use of cicletanine as a monotherapy or in combination with other agents for treatment of disease. Cicletanine, as either a monotherapy or in combination with other drugs, may have the form of a non-racemic mixture of the negative (-) and positive (+) enantiomers of cicletanine, or as either the (-) or (+) enantiomer alone.
PCT/US2005/034763 2004-09-22 2005-09-22 Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease Ceased WO2006034510A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05800096A EP1804795A4 (en) 2004-09-22 2005-09-22 Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
CA002581337A CA2581337A1 (en) 2004-09-22 2005-09-22 Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US61232304P 2004-09-22 2004-09-22
US61236904P 2004-09-22 2004-09-22
US60/612,369 2004-09-22
US60/612,323 2004-09-22
US11/035,308 2005-01-13
US11/035,308 US20060153934A1 (en) 2005-01-13 2005-01-13 Combination therapies of cicletanine and magnesium
US11/035,328 US20060154959A1 (en) 2005-01-13 2005-01-13 Combination therapies of cicletanine and carvedilol
US11/035,328 2005-01-13
US11/035,231 US20060154971A1 (en) 2005-01-13 2005-01-13 Combination therapies of cicletanine and lacidipine
US11/035,231 2005-01-13
US68468405P 2005-05-26 2005-05-26
US60/684,684 2005-05-26
US11/232,724 2005-09-21
US11/232,724 US20060089374A1 (en) 2003-07-17 2005-09-21 Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease

Publications (2)

Publication Number Publication Date
WO2006034510A2 WO2006034510A2 (en) 2006-03-30
WO2006034510A3 true WO2006034510A3 (en) 2006-06-01

Family

ID=36090724

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/034763 Ceased WO2006034510A2 (en) 2004-09-22 2005-09-22 Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease

Country Status (3)

Country Link
EP (1) EP1804795A4 (en)
CA (1) CA2581337A1 (en)
WO (1) WO2006034510A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
TWI513462B (en) * 2009-11-13 2015-12-21 Toray Industries Therapeutic or preventive agents for diabetes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383998A (en) * 1981-02-10 1983-05-17 Societe De Conseils De Recherches Et D'applications Scientifiques Furo-(3,4-c)-pyridine derivatives and their pharmaceutical use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2148082A1 (en) * 1993-09-03 1995-03-09 Daisuke Machii Imidazoquinazoline derivatives
HUP0300990A2 (en) * 2003-04-15 2005-05-30 SynoSens Kutató és Fejlesztő Kft. Synergistic combination for the prophylaxis and treatment of diabetes
WO2005009446A1 (en) * 2003-07-17 2005-02-03 Cotherix, Inc. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
US20050113314A1 (en) * 2003-08-29 2005-05-26 Fong Benson M. Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383998A (en) * 1981-02-10 1983-05-17 Societe De Conseils De Recherches Et D'applications Scientifiques Furo-(3,4-c)-pyridine derivatives and their pharmaceutical use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1804795A4 *

Also Published As

Publication number Publication date
EP1804795A2 (en) 2007-07-11
WO2006034510A2 (en) 2006-03-30
CA2581337A1 (en) 2006-03-30
EP1804795A4 (en) 2007-11-07

Similar Documents

Publication Publication Date Title
EP1933833B8 (en) Therapy for the treatment of overactive bladder
EP2371853A3 (en) Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment
EP2168962A3 (en) Phenylacetamides and their use as glucokinase modulators
EP2526933A3 (en) Inhibitors of bruton's tyrosine kinase
MY143795A (en) Tetrahydropyridoindole derivatives
WO2006034373A8 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
WO2007137247A3 (en) Treatment for depressive disorders
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
WO2006070325A3 (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
EP2392322A3 (en) Dosing regimes for trans-clomiphene
WO2004096118A3 (en) Composition for improving cognition and memory
WO2008032222A3 (en) Treatment of vertigo with acetyl-l-leucine
WO2006034510A3 (en) Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
WO2008085872A8 (en) Cicletanine and pkc inhibitors in the treatment of pulmonary and cardiac disorders
WO2007056454A3 (en) Use of cicletanine and other furopyridines for treatment of hypertension
GB0606001D0 (en) Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
WO2005092878A3 (en) Schweinfurthin analogues
WO2006064228A3 (en) Thiazolopyramidine compounds for the modulation of chemokine receptor activity
EP1033133A4 (en) Composition for treatment of diabetes and treatment of diabetes
WO2005120518A3 (en) Use of atp analogues for treatment of cardiovascular diseases
WO2006012438A3 (en) Compositions and methods for treatment and prevention of insulin resistance
EA200970877A1 (en) COMPOSITION SUITABLE FOR THE PREVENTION OF TYPE 2 DIABETES AND ITS COMPLICATIONS IN PATIENTS WITH PREDIABETES WITH INSULIN RESISTANCE
WO2006128035A3 (en) Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2581337

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3003/DELNP/2007

Country of ref document: IN

Ref document number: 2005800096

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005800096

Country of ref document: EP